751 related articles for article (PubMed ID: 32951239)
21. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM
Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066
[TBL] [Abstract][Full Text] [Related]
22. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
[TBL] [Abstract][Full Text] [Related]
24. Pediatric chronic spontaneous urticaria: a brief clinician's guide.
Votto M; Achilli G; De Filippo M; Licari A; Marseglia A; Moiraghi A; Di Sabatino A; Marseglia GL
Expert Rev Clin Immunol; 2022 Sep; 18(9):889-899. PubMed ID: 35833360
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria.
Sánchez J; Zakzuk J; Cardona R
J Allergy Clin Immunol Pract; 2018; 6(1):177-182.e1. PubMed ID: 28709817
[TBL] [Abstract][Full Text] [Related]
26. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature.
Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB
Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910
[TBL] [Abstract][Full Text] [Related]
27. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
29. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
[TBL] [Abstract][Full Text] [Related]
30. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.
Maurer M; Zuberbier T; Metz M
Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278
[TBL] [Abstract][Full Text] [Related]
31. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
[TBL] [Abstract][Full Text] [Related]
32. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
[TBL] [Abstract][Full Text] [Related]
33. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
34. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
36. Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.
Sirufo MM; Bassino EM; De Pietro F; Ginaldi L; De Martinis M
Int J Immunopathol Pharmacol; 2021; 35():20587384211065870. PubMed ID: 35170369
[TBL] [Abstract][Full Text] [Related]
37. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
38. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
Abe N; Bohgaki M; Kasahara H
Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
[TBL] [Abstract][Full Text] [Related]
39. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
40. Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don't Know.
Terhorst-Molawi D; Fox L; Siebenhaar F; Metz M; Maurer M
Am J Clin Dermatol; 2023 May; 24(3):397-404. PubMed ID: 36810982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
